Epigral Limited Business Intelligence Report
Epigral Limited Business Intelligence Report
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
Epigral Limited, formerly Meghmani Finechem, is a leading integrated chemical manufacturer in India specializing in the Chlor-Alkali and Speciality Chemicals value chains. The business has successfully transitioned from a commodity-heavy portfolio to high-value derivatives, which now represent approximately 52% of the projected revenue mix. Management has demonstrated significant execution capabilities by commissioning large-scale projects like CPVC resin and Epichlorohydrin plants. Despite cyclical volatility in the chemical sector, the company maintains a robust market position as a top-5…
Key Changes in FY2026
The business has undergone a significant transformation from a commodity-focused Chlor-Alkali player (formerly Meghmani Finechem) to an integrated specialty chemical powerhouse renamed Epigral. The strategic shift is quantified by the Derivatives & Specialty segment growing from 25% of revenue in FY22 to a projected 52% by FY26. This evolution is driven by moving up the value chain into Chloromethanes, Hydrogen Peroxide, and CPVC resin, reducing the company's historical vulnerability to ECU (Electrochemical Unit) price volatility. The company is now the 6th largest producer of Chloromethanes in India, showcasing successful scale-up capabilities. The recent incorporation of an Advanced Materials subsidiary further underscores this evolution towards high-entry-barrier chemistry. The…
Management Commentary
The management team has shown strong strategic foresight by rebranding to 'Epigral' to reflect their shift toward specialized chemical value chains. Execution has been reliable, with multiple complex chemical units commissioned on or near schedule. Disclosure quality is high, evidenced by frequent investor interactions, detailed quarterly presentations, and clear segment reporting. The promotion of professional management alongside the founding family suggests an evolution toward better corporate structure. However, the business remains closely held by the promoter group at 68.83%, which centralizes decision-making. Overall, management execution is rated as strong based on the successful diversification of the revenue base.
Financial Highlights
The business has delivered a 5-year sales CAGR of 25% and a profit CAGR of 27%, indicating high-quality historical growth. Operating margins (OPM) have historically been strong, peaking at 33% before moderating to the 22-25% range as the product mix evolves and industry cycles shift. Return on Equity (ROE) remains healthy at 16%, though down from its high of 24%, reflecting the capital-intensive nature of recent expansions. Interest coverage and debt-to-equity ratios are well-managed, with borrowings decreasing from 993 Cr in 2022 to 572 Cr in 2026. This financial profile suggests a business that uses leverage effectively to build productive assets without overextending its balance sheet.
Major Opportunities
- Leading integrated manufacturer of chemicals in India
- Strategic shift toward high-margin Specialty Chemicals (52% mix target)
- Strong cash flow conversion history (CFO/OP often > 90%)
Major Risks
- Significant erosion in Operating Profit Margins (32% to 22%)
- ROCE halved from 32% peak to 15% currently
- Debtor days recently doubled, impacting working capital efficiency
About Epigral Limited's Annual Report & Financial Performance
The latest Epigral Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this Epigral Limited research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
Epigral Limited — Frequently Asked Questions
Explore more Epigral Limited research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.